PRESS RELEASE published on 08/20/2026 at 18:00, 22 days 19 hours ago Ipsen - Juillet 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle sur le nombre de droits de vote et d'actions d'une société cotée sur Euronext Paris. Détails des droits de vote bruts et nets Euronext Paris Droits De Vote Capital Social Actions Franchissements De Seuils
PRESS RELEASE published on 08/20/2026 at 18:00, 22 days 19 hours ago Ipsen - July 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information on total number of voting rights and shares for a company listed on Euronext Paris Euronext Paris Voting Rights Shares ISIN Code Total Number
BRIEF published on 07/24/2026 at 10:01, 1 month 19 days ago BlackRock Inc. réduit sa participation dans IPSEN SA Droits De Vote Franchissement De Seuil Actions BlackRock Ipsen SA
BRIEF published on 07/24/2026 at 10:01, 1 month 19 days ago BlackRock Inc. reduces its stake in IPSEN SA Voting Rights Actions BlackRock Threshold Crossing Ipsen SA
PRESS RELEASE published on 07/24/2026 at 09:56, 1 month 19 days ago Franchissement de seuil BlackRock Inc. declares crossing below 5% threshold in IPSEN SA capital and voting rights on July 6, 2026 Déclaration BlackRock Inc. Threshold Crossing Ipsen SA Capital Decrease
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago Mise à jour sur l'essai BOLD de phase III d'Ipsen dans l'atrésie des voies biliaires Recherche Clinique Odevixibat Atrésie Des Voies Biliaires Essai BOLD De Phase III Transplantation Hépatique
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago Update on Ipsen's Phase III BOLD Trial in Biliary Atresia Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 19 days ago Ipsen fait le point sur l'essai de Phase III BOLD dans l'atrésie des voies biliaires Ipsen annonce que l'essai de Phase III BOLD pour l'atrésie des voies biliaires n'a pas atteint son critère principal. Les données confirment le profil de sécurité de l'odévixibat Ipsen Essai De Phase III Odevixibat Atrésie Des Voies Biliaires BOLD
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 19 days ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 2 months 3 days ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
Published on 09/12/2026 at 02:35, 11 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 35 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 30 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 10 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 35 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 5 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 20 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 25 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 51 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 20 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
